2025 Q4 -tulosraportti
Vain PDF
6 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 40 | - | - | ||
| 210 | - | - | ||
| 50 | - | - | ||
| 2 450 | - | - | ||
| 1 133 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
5 min sitten5 min sittenTämä julkaisu on poistettu.
·20 min sittenOne influences just as many on sharewille as one does if one stands on the veranda and shouts out into the courtyard. If one influences one or 3, the price won't budge a single øre.The sad thing is that people don't understand it. 180 million in turnover, you won't get it up an øre even if you get 20 people involved, then there must be large trading. But having the boss himself Erik on sharewille is really awesome then, good that you exposed him 😂·16 min sittenThis is probably a person with good insight, but unfortunately, we probably don't have management on our side here, even if we wished we did. However, writers who clearly understand many of the things I'm wondering about are invaluable for my own investment.
·2 t sittenIT STARTS NOW. 🧬🚀 Most people think we are in the middle of the game. We are not. We are just at the beginning. Think about what management has spent the last two years on: Funding rounds. Investor meetings. Negotiations with bondholders. Share issues. New share issues. Cost cuts. Voluntary pay cuts to keep the lights on. That is the reality behind the scenes for a small listed biotech company without revenues. While Thomas Hansen and the team in Stockholm worked in the lab – Erik and Lubor spent disproportionately much energy ensuring there was money for the next month. It's over now. For the first time in Circios' history, management can wake up in the morning and think about one thing: The research. 250 million in cash. Runway until 2030. No stressed share issues. No desperate negotiations. Just a team that can finally sit down and accelerate what they always knew they could build. In vivo studies that were previously too expensive. New tissues. New disease models. Parallel tracks that were not possible before. But – and this is important – this is still a long-term game. We are in preclinical phase. Data takes time. Deals take time. Boston in May is one step. Q2 data is one step. He who expects an explosion next week misunderstands what we own. He who understands that we have just received the starting signal – sleeps well. We know what we own. ♟️🧱🍷- ·2 t sittenWHILE OTHER BIOTECH COMPANIES BURN CASH – THEY BUILT AN EMPIRE. 🔥🧬 There's something happening in the biotech industry that most investors never talk about. Companies raise hundreds of millions. Hire 200 people. Rent luxury offices. Burn $10-20 million a month. And continue to raise more capital – quarter after quarter – even if results fail to materialize. Until the cash is empty and shareholders are left with nothing. That's not how Circio was run. In Q4 2024 and throughout 2025, CEO Erik Wiklund and CFO Lubor Gaal voluntarily took pay cuts. Not because anyone forced them. But because they chose to prioritize research over their own salaries. 9 employees. Lean organization. Tight cost control. While other biotech companies burn $10-20 million a month – Circio kept costs to a minimum and still delivered results that made Big Pharma knock on their door. And what did they get in return? First Big Pharma deal in Circio's history. 250 million oversubscribed. Runway until 2030. Oral presentation in Boston. And now – in the middle of a $14 billion race for circular RNA. All this was built on discipline, not money. Most companies buy success. Circio earned theirs. We know what we own. ♟️🧱🍷
·3 t sittenDo we know anything about who bought shares in the share issue, and do we know anything about which of these have remained invested in the share through the dip in recent days? Can anyone provide information about this?
·2 t sittenTake it with a pinch of salt, but heard very many said they sold almost immediately. Fastest profit ever for them.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
6 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 5 min sitten5 min sittenTämä julkaisu on poistettu.·20 min sittenOne influences just as many on sharewille as one does if one stands on the veranda and shouts out into the courtyard. If one influences one or 3, the price won't budge a single øre.The sad thing is that people don't understand it. 180 million in turnover, you won't get it up an øre even if you get 20 people involved, then there must be large trading. But having the boss himself Erik on sharewille is really awesome then, good that you exposed him 😂·16 min sittenThis is probably a person with good insight, but unfortunately, we probably don't have management on our side here, even if we wished we did. However, writers who clearly understand many of the things I'm wondering about are invaluable for my own investment.
- ·2 t sittenIT STARTS NOW. 🧬🚀 Most people think we are in the middle of the game. We are not. We are just at the beginning. Think about what management has spent the last two years on: Funding rounds. Investor meetings. Negotiations with bondholders. Share issues. New share issues. Cost cuts. Voluntary pay cuts to keep the lights on. That is the reality behind the scenes for a small listed biotech company without revenues. While Thomas Hansen and the team in Stockholm worked in the lab – Erik and Lubor spent disproportionately much energy ensuring there was money for the next month. It's over now. For the first time in Circios' history, management can wake up in the morning and think about one thing: The research. 250 million in cash. Runway until 2030. No stressed share issues. No desperate negotiations. Just a team that can finally sit down and accelerate what they always knew they could build. In vivo studies that were previously too expensive. New tissues. New disease models. Parallel tracks that were not possible before. But – and this is important – this is still a long-term game. We are in preclinical phase. Data takes time. Deals take time. Boston in May is one step. Q2 data is one step. He who expects an explosion next week misunderstands what we own. He who understands that we have just received the starting signal – sleeps well. We know what we own. ♟️🧱🍷
- ·2 t sittenWHILE OTHER BIOTECH COMPANIES BURN CASH – THEY BUILT AN EMPIRE. 🔥🧬 There's something happening in the biotech industry that most investors never talk about. Companies raise hundreds of millions. Hire 200 people. Rent luxury offices. Burn $10-20 million a month. And continue to raise more capital – quarter after quarter – even if results fail to materialize. Until the cash is empty and shareholders are left with nothing. That's not how Circio was run. In Q4 2024 and throughout 2025, CEO Erik Wiklund and CFO Lubor Gaal voluntarily took pay cuts. Not because anyone forced them. But because they chose to prioritize research over their own salaries. 9 employees. Lean organization. Tight cost control. While other biotech companies burn $10-20 million a month – Circio kept costs to a minimum and still delivered results that made Big Pharma knock on their door. And what did they get in return? First Big Pharma deal in Circio's history. 250 million oversubscribed. Runway until 2030. Oral presentation in Boston. And now – in the middle of a $14 billion race for circular RNA. All this was built on discipline, not money. Most companies buy success. Circio earned theirs. We know what we own. ♟️🧱🍷
- ·3 t sittenDo we know anything about who bought shares in the share issue, and do we know anything about which of these have remained invested in the share through the dip in recent days? Can anyone provide information about this?·2 t sittenTake it with a pinch of salt, but heard very many said they sold almost immediately. Fastest profit ever for them.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 40 | - | - | ||
| 210 | - | - | ||
| 50 | - | - | ||
| 2 450 | - | - | ||
| 1 133 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
6 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 5 min sitten5 min sittenTämä julkaisu on poistettu.·20 min sittenOne influences just as many on sharewille as one does if one stands on the veranda and shouts out into the courtyard. If one influences one or 3, the price won't budge a single øre.The sad thing is that people don't understand it. 180 million in turnover, you won't get it up an øre even if you get 20 people involved, then there must be large trading. But having the boss himself Erik on sharewille is really awesome then, good that you exposed him 😂·16 min sittenThis is probably a person with good insight, but unfortunately, we probably don't have management on our side here, even if we wished we did. However, writers who clearly understand many of the things I'm wondering about are invaluable for my own investment.
- ·2 t sittenIT STARTS NOW. 🧬🚀 Most people think we are in the middle of the game. We are not. We are just at the beginning. Think about what management has spent the last two years on: Funding rounds. Investor meetings. Negotiations with bondholders. Share issues. New share issues. Cost cuts. Voluntary pay cuts to keep the lights on. That is the reality behind the scenes for a small listed biotech company without revenues. While Thomas Hansen and the team in Stockholm worked in the lab – Erik and Lubor spent disproportionately much energy ensuring there was money for the next month. It's over now. For the first time in Circios' history, management can wake up in the morning and think about one thing: The research. 250 million in cash. Runway until 2030. No stressed share issues. No desperate negotiations. Just a team that can finally sit down and accelerate what they always knew they could build. In vivo studies that were previously too expensive. New tissues. New disease models. Parallel tracks that were not possible before. But – and this is important – this is still a long-term game. We are in preclinical phase. Data takes time. Deals take time. Boston in May is one step. Q2 data is one step. He who expects an explosion next week misunderstands what we own. He who understands that we have just received the starting signal – sleeps well. We know what we own. ♟️🧱🍷
- ·2 t sittenWHILE OTHER BIOTECH COMPANIES BURN CASH – THEY BUILT AN EMPIRE. 🔥🧬 There's something happening in the biotech industry that most investors never talk about. Companies raise hundreds of millions. Hire 200 people. Rent luxury offices. Burn $10-20 million a month. And continue to raise more capital – quarter after quarter – even if results fail to materialize. Until the cash is empty and shareholders are left with nothing. That's not how Circio was run. In Q4 2024 and throughout 2025, CEO Erik Wiklund and CFO Lubor Gaal voluntarily took pay cuts. Not because anyone forced them. But because they chose to prioritize research over their own salaries. 9 employees. Lean organization. Tight cost control. While other biotech companies burn $10-20 million a month – Circio kept costs to a minimum and still delivered results that made Big Pharma knock on their door. And what did they get in return? First Big Pharma deal in Circio's history. 250 million oversubscribed. Runway until 2030. Oral presentation in Boston. And now – in the middle of a $14 billion race for circular RNA. All this was built on discipline, not money. Most companies buy success. Circio earned theirs. We know what we own. ♟️🧱🍷
- ·3 t sittenDo we know anything about who bought shares in the share issue, and do we know anything about which of these have remained invested in the share through the dip in recent days? Can anyone provide information about this?·2 t sittenTake it with a pinch of salt, but heard very many said they sold almost immediately. Fastest profit ever for them.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 40 | - | - | ||
| 210 | - | - | ||
| 50 | - | - | ||
| 2 450 | - | - | ||
| 1 133 | - | - |
Välittäjätilasto
Dataa ei löytynyt